Itrifal Shahtara for Eczema (Nar Farsi): A Comprehensive Review of Phytochemistry, Mechanisms, and Therapeutic Relevance

Background: Eczema (Nar Farsi) is a chronic inflammatory skin disorder marked by pruritus, immune dysregulation, and epidermal barrier dysfunction, significantly affecting quality of life. Long-term use of conventional therapies such as corticosteroids and immune-suppressants is often limited by adverse effects. Unani medicine offers several time-tested polyherbal formulations for chronic skin diseases, among which Itrifal Shahtara is traditionally prescribed for pruritic and inflammatory dermatoses. Objective: To evaluate the therapeutic relevance of Itrifal Shahtara in eczema by correlating its phytochemical constituents with known disease mechanisms. Methods: A narrative review was conducted using electronic databases (PubMed, Google Scholar, ScienceDirect, Elsevier, ResearchGate) and classical Unani literature. Experimental studies, clinical reports, and pharmacological evidence related to the formulation’s constituents were analyzed. Results: The constituents of Itrifal Shahtara exhibit anti-inflammatory, immunomodulatory, antioxidant, anti-pruritic, antimicrobial, and skin barrier–supportive activities. These effects are mediated through modulation of cytokine pathways, reduction of oxidative stress, suppression of inflammatory mediators, and improvement of epidermal integrity. Discussion and Conclusion: The multi-targeted pharmacological actions of Itrifal Shahtara align with both Unani principles and contemporary understanding of eczema pathogenesis, supporting its potential role as a safer long-term therapeutic option. However, rigorously designed clinical trials are required to validate its efficacy, safety, and standardization Keywords: Eczema; Nar Farsi; Itrifal Shahtara; Unani medicine; Phytochemistry; Anti-inflammatory agents